Please assess the completion status of the following clinical trial:

Trial Title: Safety and Compliance of Taking Mesalamine Once a Day in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 6 to 18 years,~* Must be able to swallow tablets, and~* Biopsy proven ulcerative colitis~Exclusion Criteria:~* Allergy or hypersensitivity to Mesalamine or other salicylates~* Use of rectal medications

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Asacol once a day dosing (Type: EXPERIMENTAL): Asacol total dose in mg/kg given once a day
- Asacol BID/TID dosing (Type: ACTIVE_COMPARATOR): Asacol total dose split BID or TID

Based on this trial design, predict the completion outcome and termination type (if applicable).